cannabis/atrophy

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.

FIELD OF THE INVENTION The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions

FIELD OF THE INVENTION The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that

FIELD OF THE INVENTION The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that

RELATED APPLICATIONS This application is a national stage filing under 35 U.S.C. .sctn. 371 of international application PCT/GB2007/000122, filed Jan. 17, 2007, which was published under PCT Article 21(2) in English. FIELD OF THE INVENTION The present invention relates to the use of

FIELD OF THE INVENTION The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. BACKGROUND TO THE INVENTION Neural degeneration, or neurodegeneration, can be described as the progressive damage or death of neurones.